LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

Kenneth Blum, Amanda L.C. Chen, Thomas J.H. Chen, Patrick Rhoades, Thomas J. Prihoda, B. William Downs, Roger L. Waite, Lonna Williams, Eric R. Braverman, Dasha Braverman, Vanessa Arcuri, Mallory Kerner, Seth H. Blum, Tomas Palomo

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Introduction: This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen® , Inc., La Jolla, CA, USA). Methods: A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed. Results: Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-ã2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045). Conclusion: If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.

Original languageEnglish (US)
Pages (from-to)894-913
Number of pages20
JournalAdvances in Therapy
Volume25
Issue number9
DOIs
StatePublished - Sep 11 2008

    Fingerprint

Keywords

  • LG839
  • Neurotransmitters
  • Obesity
  • Reward deficiency syndrome
  • Sugar craving behavior
  • Weight loss

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Blum, K., Chen, A. L. C., Chen, T. J. H., Rhoades, P., Prihoda, T. J., Downs, B. W., Waite, R. L., Williams, L., Braverman, E. R., Braverman, D., Arcuri, V., Kerner, M., Blum, S. H., & Palomo, T. (2008). LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. Advances in Therapy, 25(9), 894-913. https://doi.org/10.1007/s12325-008-0093-z